On March 3, 2014 Dendreon Corporation reported results for the fourth quarter and full year ended December 31, 2013. Net product revenue for the year ended December 31, 2013 was $283.7 million compared to $325.3 million for the year ended December 31, 2012 (Press release Dendreon, MAR 3, 2014, View Source [SID:1234500204]). Net product revenue for the fourth quarter ended December 31, 2013 was $74.8 million compared to $81.6 million on a pro-forma basis for the fourth quarter ended December 31, 2012, which excludes a $3.8 million favorable adjustment to the Company’s chargebacks reserve due to a change in estimate.
New commercial model in place to improve execution with Silvio Pacheco as Chief Customer Officer and Bill Jenkinson as Chief Marketing Officer. Dendreon is advancing automation efforts in the U.S. which is key to lower COGS in U.S. and also more efficiently make PROVENGE available worldwide. As a first step, Dendreon will make PROVENGE available in Europe through Centers of Excellence using Contract Manufacturing Organization (PharmaCell), beginning with Germany and the United Kingdom.